Published in Cardiovascular Business Week, January 9th, 2007
Under terms of this agreement, Lab21 will have exclusive rights in the U.K. and Ireland to market and sell Clinical Data's Familion test, a genetic test designed to identify mutations in people with inherited cardiac channelopathies such as Long QT Syndrome (LQTS) and Brugada Syndrome. In addition, the parties have agreed to consider other proprietary, molecular and pharmacogenomic tests developed and commercialized by PGxHealth for future launch in the U.K. and Ireland.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.